PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients Assessment of the Correlation Between Body Mass Index and Recurrence Among Zoladex Treated Prostate Cancer Patients
Observational Model: Cohort, Time Perspective: Prospective
Percentage recurrence rate among normal weight and overweight or obese prostate cancer patients treated by adjuvant Zoladex therapy.
Every 3 months
Budapest City's Local Government "Péterfy Sándor" Hospital and Ambulatory Clinic
Hungary: National Institute of Pharmacy